Reliquet V - Search Results

1

Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure.

André-Garnier E, Hingrat QL, Marcelin AG, Reliquet V, Malet I, Leducq V, Rodallec A, Peytavin G, Ferré V, Charpentier C, Raffi F. André-Garnier E, et al. Among authors: reliquet v. Int J Antimicrob Agents. 2020 Aug;56(2):106039. doi: 10.1016/j.ijantimicag.2020.106039. Epub 2020 May 29. Int J Antimicrob Agents. 2020. PMID: 32479891 No abstract available.

2

No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors.

Dailly E, Billaud E, Reliquet V, Breurec S, Perré P, Léautez S, Jolliet P, Bourin M, Raffi F. Dailly E, et al. Among authors: reliquet v. Eur J Clin Pharmacol. 2004 Jul;60(5):343-8. doi: 10.1007/s00228-004-0769-5. Epub 2004 May 20. Eur J Clin Pharmacol. 2004. PMID: 15156302

3

A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients.

Dailly E, Reliquet V, Raffi F, Jolliet P. Dailly E, et al. Among authors: reliquet v. Eur J Clin Pharmacol. 2005 Apr;61(2):153-6. doi: 10.1007/s00228-005-0900-2. Epub 2005 Mar 11. Eur J Clin Pharmacol. 2005. PMID: 15761750 Clinical Trial.

4

Disturbance of apolipoprotein B100 containing lipoprotein metabolism in severe hyperlipidemic and lipodystrophic HIV patients on combined antiretroviral therapy: evidences of insulin resistance effect.

Ouguerram K, Zair Y, Billon S, Chétiveaux M, Brunet-François C, Ngohou-Bach K, Allavena C, Reliquet V, Milpied B, Magot T, Raffi F, Krempf M. Ouguerram K, et al. Among authors: reliquet v. Med Chem. 2008 Nov;4(6):544-50. doi: 10.2174/157340608786242061. Med Chem. 2008. PMID: 18991738

5

Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.

Chaix ML, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, Schneider V, Izopet J, Masquelier B, Rouzioux C, Meyer L, Costagliola D; ANRS AC11 Resistance Group; Cohort PRIMO ANRS CO 6; FHDH ANRS CO4 Study Groups. Chaix ML, et al. AIDS. 2009 Mar 27;23(6):717-24. doi: 10.1097/QAD.0b013e328326ca77. AIDS. 2009. PMID: 19279445

6

Twelve-year experience of nevirapine use: benefits and convenience for long-term management in a French cohort of HIV-1-infected patients.

Reliquet V, Allavena C, Morineau-Le Houssine P, Mounoury O, Raffi F. Reliquet V, et al. HIV Clin Trials. 2010 Mar-Apr;11(2):110-7. doi: 10.1310/hct1102-110. HIV Clin Trials. 2010. PMID: 20542847

7

Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacological parameters.

Dailly E, Rodallec A, Allavena C, Deslandes G, Garnier E, Billaud E, Ferré V, Reliquet V, Bouquié R, Raffi F, Jolliet P. Dailly E, et al. Among authors: reliquet v. Fundam Clin Pharmacol. 2012 Aug;26(4):538-42. doi: 10.1111/j.1472-8206.2011.00949.x. Epub 2011 May 5. Fundam Clin Pharmacol. 2012. PMID: 21545648

8

Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen.

Allavena C, Rodallec A, Sécher S, Reliquet V, Baffoin S, André-Garnier E, Billaud E, Raffi F, Ferré V. Allavena C, et al. Among authors: reliquet v. J Med Virol. 2013 Nov;85(11):1878-82. doi: 10.1002/jmv.23679. Epub 2013 Jul 16. J Med Virol. 2013. PMID: 23861166

9

Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.

Reliquet V, Chirouze C, Allavena C, Muret P, Peytavin G, André-Garnier E, Bettinger D, Ferré V, Hoen B, Raffi F. Reliquet V, et al. Antivir Ther. 2014;19(1):117-23. doi: 10.3851/IMP2691. Epub 2013 Oct 22. Antivir Ther. 2014. PMID: 24145365

10

The spectrum of HIV mother-to-child transmission risk.

Reliquet V, Winer N, Chereau N, Launay E, Lamberet A, Andre-Garnier E, Raffi F, Brunet C. Reliquet V, et al. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19703. doi: 10.7448/IAS.17.4.19703. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397451 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

158 results

Search Page